Carcinogenesis, Vol. 20, No. 7, 1235-1240,
July 1999
© 1999 Oxford University Press
Molecular Epidemiology And Cancer Prevention |
Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci
Institut für Physiologische Chemie 1, Heinrich Heine Universität, Postfach 101007, D-40001 Düsseldorf, Germany,
1 Clinical Biochemistry Research Laboratory, School of Postgraduate Medicine, Keele University, Centre for Cell & Molecular Medicine, North Staffordshire Hospital, Hartshill, Stoke-on-Trent, Staffordshire ST4 7QB,
2 Department of Dermatology, North Staffordshire Hospital, Stoke-on-Trent, Staffordshire,
3 Department of Dermatology, Royal Cornwall Hospitals, Truro, Cornwall and
4 Department of Mathematics, Keele University, Staffordshire, UK
Glutathione S-transferase GSTM1 B and GSTT1 null, and cytochrome P450 CYP2D6 EM have been associated with cutaneous basal cell carcinoma (BCC) numbers, although their quantitative effects show that predisposition to many BCC is determined by an unknown number of further loci. We speculate that other loci that determine response to oxidative stress, such as NAD(H):quinone oxidoreductase (NQO1) are candidates. Accordingly, we assessed the association between NQO1 null and BCC numbers primarily to rank NQO1 null in a model that included genotypes already associated with BCC numbers. We found that only 14 out of 457 cases (3.1%) were NQO1 null. This frequency did not increase in cases with characteristics linked with BCC numbers including gender, skin type, a truncal lesion or more than one new BCC at any presentation (MPP). However, the mean number of BCC in NQO1*0 homozygotes was greater than in wild-type allele homozygotes and heterozygotes, although the difference was not quite significant (P = 0.06). These data reflect the link between NQO1 null and BCC numbers in the 42 MPP cases rather than the whole case group. We identified an interaction between NQO1 null and GSTT1 null that was associated with more BCC (P = 0.04), although only four cases had this combination. The relative influence of NQO1 null was studied in a multivariate model that included: (i) 241 patients in whom GSTM1 B, GSTT1 null and CYP2D6 EM genotype data were available, and (ii) 101 patients in whom these genotypes, as well as data on GSTM3, CYP1A1 and melanocyte-stimulating hormone receptor (MC1R) genotypes were available. NQO1 null (P = 0.001) and MC1R asp294/asp294 (P = 0.03) were linked with BCC numbers, and the association with CYP2D6 EM approached significance (P = 0.08). In a stepwise regression model only these genotypes were significantly associated with BCC numbers with NQO1 null being the most powerful predictor.
Abbreviations: BCC, cutaneous basal cell carcinoma; MC1R, melanocyte-stimulating hormone receptor; MPP,multiple presentation phenotype; NQO1, quinone oxidoreductase; PM, poor metabolizers; ROS,reactive oxygen species; SPP, single presentation phenotype.
5 To whom correspondence should be addressed Email: paa00{at}keele.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Fu, L. Buryanovskyy, and Z. Zhang Quinone Reductase 2 Is a Catechol Quinone Reductase J. Biol. Chem., August 29, 2008; 283(35): 23829 - 23835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Dinkova-Kostova, J. W. Fahey, K. L. Wade, S. N. Jenkins, T. A. Shapiro, E. J. Fuchs, M. L. Kerns, and P. Talalay Induction of the Phase 2 Response in Mouse and Human Skin by Sulforaphane-containing Broccoli Sprout Extracts Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 847 - 851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Umemura, Y. Kuroiwa, Y. Kitamura, Y. Ishii, K. Kanki, Y. Kodama, K. Itoh, M. Yamamoto, A. Nishikawa, and M. Hirose A Crucial Role of Nrf2 in In Vivo Defense against Oxidative Damage by an Environmental Pollutant, Pentachlorophenol Toxicol. Sci., March 1, 2006; 90(1): 111 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. F. Masson, L. Sharp, S. C. Cotton, and J. Little Cytochrome P-450 1A1 Gene Polymorphisms and Risk of Breast Cancer: A HuGE Review Am. J. Epidemiol., May 15, 2005; 161(10): 901 - 915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang and G. B. Gordon A strategy for cancer prevention: Stimulation of the Nrf2-ARE signaling pathway Mol. Cancer Ther., July 1, 2004; 3(7): 885 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Siegel, D. L. Gustafson, D. L. Dehn, J. Y. Han, P. Boonchoong, L. J. Berliner, and D. Ross NAD(P)H:Quinone Oxidoreductase 1: Role as a Superoxide Scavenger Mol. Pharmacol., May 1, 2004; 65(5): 1238 - 1247. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. Wakabayashi, A. T. Dinkova-Kostova, W. D. Holtzclaw, M.-I. Kang, A. Kobayashi, M. Yamamoto, T. W. Kensler, and P. Talalay Protection against electrophile and oxidant stress by induction of the phase 2 response: Fate of cysteines of the Keap1 sensor modified by inducers PNAS, February 17, 2004; 101(7): 2040 - 2045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Stiborova, E. Frei, B. Sopko, K. Sopkova, V. Markova, M. Lankova, T. Kumstyrova, M. Wiessler, and H. H. Schmeiser Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase Carcinogenesis, October 1, 2003; 24(10): 1695 - 1703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhang, W. A. Schulz, Y. Li, R. Wang, R. Zotz, D. Wen, D. Siegel, D. Ross, H. E. Gabbert, and M. Sarbia Association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population Carcinogenesis, May 1, 2003; 24(5): 905 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Anwar, D. Dehn, D. Siegel, J. K. Kepa, L. J. Tang, J. A. Pietenpol, and D. Ross Interaction of Human NAD(P)H:Quinone Oxidoreductase 1 (NQO1) with the Tumor Suppressor Protein p53 in Cells and Cell-free Systems J. Biol. Chem., March 14, 2003; 278(12): 10368 - 10373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sorensen, H. Autrup, O. Hertel, H. Wallin, L. E. Knudsen, and S. Loft Personal Exposure to PM2.5 and Biomarkers of DNA Damage Cancer Epidemiol. Biomarkers Prev., March 1, 2003; 12(3): 191 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Winski, Y. Koutalos, D. L. Bentley, and D. Ross Subcellular Localization of NAD(P)H:quinone Oxidoreductase 1 in Human Cancer Cells Cancer Res., March 1, 2002; 62(5): 1420 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. BERGAMASCHI, G. DE PALMA, P. MOZZONI, S. VANNI, M. V. VETTORI, F. BROECKAERT, A. BERNARD, and A. MUTTI Polymorphism of Quinone-metabolizing Enzymes and Susceptibility to Ozone-induced Acute Effects Am. J. Respir. Crit. Care Med., May 1, 2001; 163(6): 1426 - 1431. [Abstract] [Full Text]
|
|
|
|
|
|
D. Siegel, A. Anwar, S. L. Winski, J. K. Kepa, K. L. Zolman, and D. Ross Rapid Polyubiquitination and Proteasomal Degradation of a Mutant Form of NAD(P)H:Quinone Oxidoreductase 1 Mol. Pharmacol., February 1, 2001; 59(2): 263 - 268. [Abstract] [Full Text]
|
|
|
|
|
|
M.J. Lafuente, X. Casterad, M. Trias, C. Ascaso, R. Molina, A. Ballesta, S. Zheng, J.K. Wiencke, and A. Lafuente NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors Carcinogenesis, October 1, 2000; 21(10): 1813 - 1819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Matthias, V. Jahnke, P. W. Jones, P. R. Hoban, J. E. Alldersea, S. F. Worrall, A. A. Fryer, and R. C. Strange Cyclin D1, Glutathione S-Transferase, and Cytochrome P450 Genotypes and Outcome in Patients with Upper Aerodigestive Tract Cancers: Assessment of the Importance of Individual Genes Using Multivariate Analysis Cancer Epidemiol. Biomarkers Prev., September 1, 1999; 8(9): 815 - 823. [Abstract] [Full Text]
|
|